Smartleaf Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$430K Buy
1,361
+158
+13% +$53.8K 0.02% 567
2025
Q4
$478K Buy
1,203
+126
+12% +$55.8K 0.02% 542
2025
Q3
$482K Buy
1,077
+483
+81% +$197K 0.03% 490
2025
Q2
$192K Sell
594
-301
-34% -$83.3K 0.02% 594
2025
Q1
$240K Buy
895
+148
+20% +$38K 0.02% 514
2024
Q4
$176K Buy
747
+306
+69% +$80.5K 0.02% 587
2024
Q3
$121K Buy
441
+326
+283% +$84.9K 0.01% 649
2024
Q2
$28.4K Buy
115
+105
+1,050% +$16.6K ﹤0.01% 901
2024
Q1
$1.54K Buy
+10
New +$1.67K ﹤0.01% 1518

Other funds holding ALNY

Smartleaf Asset Management's ALNY Position: Q1 2026 in Review

Smartleaf Asset Management increased its Alnylam Pharmaceuticals (ALNY) stake by 13% in Q1 2026, buying an estimated $53.8K and bringing the position to 1,361 shares worth $430K. The position accounts for 0.02% of the portfolio, ranked #567.

Smartleaf Asset Management first reported a position in ALNY in Q1 2024 and has held it in 9 quarters since. The position peaked at $482K in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Smartleaf Asset Management held 1,361 shares of Alnylam Pharmaceuticals worth $430K as of Q1 2026.
  • Smartleaf Asset Management bought 158 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $53.8K.
  • Alnylam Pharmaceuticals made up 0.02% of Smartleaf Asset Management's portfolio in Q1 2026, its #567 holding.
  • Smartleaf Asset Management first reported a position in Alnylam Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • Smartleaf Asset Management's Alnylam Pharmaceuticals position peaked at $482K in Q3 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.